Latest News - Phase 3/4 Trials

Friday, May 12, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results

New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, pati…

Read the full story

Tuesday, April 04, 2017 | FDA Approval/Clearance, Movement Disorders, Neuromuscular & Immune Disorders, Phase 3/4 Trials

New Therapy for Chorea Associated with Huntington’s Disease Wins FDA Approval

The FDA approved Austedo (deutetrabenazine, Teva Pharmaceuticals) tablets for the treatment of chorea associated with Huntington’s disease (HD), making it just the second product approved for th…

Read the full story

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story

Friday, February 10, 2017 | Movement Disorders, Phase 3/4 Trials

Inhaled Levodopa Impresses in Treating Parkinson’s OFF Periods in Phase 3 Study

New phase 3 data suggests that the experimental inhaled levodopa, CVT-301 (Acorda Therapeutics), may offer significant improvement in motor function in individuals with Parkinson’s disease exper…

Read the full story

Thursday, January 26, 2017 | Phase 3/4 Trials, Research and Publications, Sleep

Investigational Narcolepsy Agent Found Effective for Severely Affected Patients with Cataplexy in Phase 3 Study

Results from a phase 3 controlled trial show that pitolisant (Wakix, Bioproject Pharma) may be efficacious in severely affected narcoleptic patients with cataplexy. Pitolisant is a highly-selective hi…

Read the full story

Wednesday, January 04, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

Newly Published Phase 3 Data Boost Efficacy Profile of Ocrevus in Primary Progressive and Relapsing MS

As the FDA continues its review of the Biologics License Application (BLA) for Genentech’s Ocrevus (ocrelizumab), key phase 3 findings reviewing the agent’s safety and efficacy in relapsin…

Read the full story

Friday, December 09, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

NeuroPace Unveils New Long-Term Data for Its RNS System

At the recent American Epilepsy Society Annual Meeting in Houston, NeuroPace shared new long-term data for its RNS System for the treatment of partial-onset seizure. The RNS System monitors and respon…

Read the full story

Thursday, December 08, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

Reflecting on New Phase 3 Epidiolex Data, GW Pharmaceuticals CEO Emphasizes Education About Cannabidiol

Greenwich Biosciences, a subsidiary of GW Pharmaceuticals, shared phase 3 data in poster presentations at the recent American Epilepsy Society Annual Meeting showing that it’s investigational ca…

Read the full story

Wednesday, December 07, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

AES 2016: Sunovion Launching Phase 4 Study of Aptiom Using Wearable Technology to Detect Seizure Activity

At the recent American Epilepsy Society Annual Meeting in Houston, Sunovion revealed that will soon initiate enrollment for a Phase 4 clinical study (Study 093-701) evaluating the use of the Embrace w…

Read the full story

Thursday, December 01, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Pfizer

Adjunctive Treatment with Lyrica Found to Reduce Seizure Frequency in Pediatric Epilepsy

New phase 3 results show that Lyrica (pregabalin, Pfizer) Capsules CV is an effective adjunctive therapy for patients with epilepsy between the ages of four and 16 years of age. Specifically, the resu…

Read the full story

Thursday, November 17, 2016 | Pain & Headache, Phase 3/4 Trials, Phase 3/4 Trials, Research and Publications

Investigational Biologic for the Treatment of Migraine Shows Promise in Phase 3 Data

New Phase 3 trial results suggest that Amgen’s investigational biologic agent erenumab may be effective at reducing migraines. Erenumab was specifically designed to prevent migraine by bloc…

Read the full story

Tuesday, October 25, 2016 | Dementia & Cognitive Disorders, Phase 3/4 Trials, Research and Publications

Tramiprosate Shows Gene-Dose Effect in Alzheimer’s Patients with APOE4

New phase 3 findings suggest that the investigational amyloid-targeted agent tramiprosate may particularly effective for patients with ε4 alleles of apolipoprotein E (APOE4), a genetic risk fa…

Read the full story

Wednesday, April 13, 2016 | Phase 3/4 Trials

Investigational Primary Progressive MS Agent Shows Promise in Phase 3 Trial

An investigational agent for the treatment of primary progressive multiple sclerosis has shown considerable promise in new phase 3 data to be presented at the upcoming American Academy of Neurology An…

Read the full story

Wednesday, December 23, 2015 | Phase 3/4 Trials

Investigational Parkinson’s Agent Impresses in Phase 3 Trial

Results from the Phase 3 EASE LID clinical trial suggest that the investigational compound ADS-5102 (amantadine HCl) is effective in the treatment of levodopa-induced dyskinesia (LID) associated with …

Read the full story

Wednesday, October 28, 2015 | Phase 3/4 Trials

Amyloid Scanning Dementia Study Now Open for Registration

A new dementia study that will examine the usefulness of brain PET scans has opened registration for specialists. Scheduled to begin next year, the Imaging Dementia — Evidence for Amyloid Scanning (…

Read the full story
Load More